Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab based on early tumor shrinkage in RAS wild-type metastatic colorectal cancer: A phase II trial (HYBRID).
Arai H, Tsuda T, Sunakawa Y, Shimokawa M, Akiyoshi K, Tokunaga S, Shoji H, Kunieda K, Kotaka M, Matsumoto T, Nagata Y, Mizukami T, Mizuki F, Danenberg KD, Boku N, Nakajima TE. Arai H, et al. Among authors: shimokawa m. Cancer Med. 2024 Apr;13(7):e7107. doi: 10.1002/cam4.7107. Cancer Med. 2024. PMID: 38591098 Free PMC article. Clinical Trial.
[Studies on drug interaction of combined drug II. Interaction among isopropylantipyrine, phenacetin, allylisopropylacetylurea and caffeine on the plasma level of isopropylantipyrine and phenacetin in dogs (author's transl)].
Nakajima T, Okada T, Takeuchi S, Shimokawa M, Kuruma I. Nakajima T, et al. Among authors: shimokawa m. Yakugaku Zasshi. 1977 Jun;97(6):607-12. doi: 10.1248/yakushi1947.97.6_607. Yakugaku Zasshi. 1977. PMID: 925850 Japanese. No abstract available.
New predictors of microvascular invasion for small hepatocellular carcinoma ≤ 3 cm.
Fukushima R, Harimoto N, Okuyama T, Seki T, Hoshino K, Hagiwara K, Kawai S, Ishii N, Tsukagoshi M, Igarashi T, Araki K, Tomonaga H, Higuchi T, Shimokawa M, Shirabe K. Fukushima R, et al. Among authors: shimokawa m. Int J Clin Oncol. 2024 May 20. doi: 10.1007/s10147-024-02553-9. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38769190
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Nosaki K, Yoh K, Toyozawa R, Horinouchi H, Morise M, Ohashi K, Murakami H, Satouchi M, Sakakibara-Konishi J, Yano S, Okumura F, Matsumoto S, Shimokawa M, Seto T, Goto K. Nosaki K, et al. Among authors: shimokawa m. Int J Clin Oncol. 2024 May 17. doi: 10.1007/s10147-024-02543-x. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38758397
Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas.
Nakashoji A, Haratake N, Bhattacharya A, Mao W, Xu K, Wang K, Daimon T, Ozawa H, Shigeta K, Fushimi A, Yamashita N, Morimoto Y, Shimokawa M, Saito S, Egloff AM, Uppaluri R, Long MD, Kufe D. Nakashoji A, et al. Among authors: shimokawa m. Cancer Res Commun. 2024 May 14;4(5):1268-1281. doi: 10.1158/2767-9764.CRC-24-0011. Cancer Res Commun. 2024. PMID: 38619287 Free PMC article.
Author Correction: C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Shirakawa T, Makiyama A, Shimokawa M, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E. Shirakawa T, et al. Among authors: shimokawa m. Sci Rep. 2024 Mar 4;14(1):5311. doi: 10.1038/s41598-024-55673-7. Sci Rep. 2024. PMID: 38438505 Free PMC article. No abstract available.
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation - A real-world database study in Japan: The CReGYT-01 EGFR study.
Katsumata S, Shimokawa M, Hamada A, Haratake N, Nomura K, Fujino K, Yoshikawa M, Suzawa K, Shien K, Suda K, Ohara S, Fukuda S, Kinoshita F, Hayasaka K, Notsuda H, Takamori S, Muto S, Takanashi Y, Mizuno K, Kawase A, Hayakawa T, Sekihara K, Toda M, Matsuo S, Takegahara K, Hashimoto M, Nakahashi K, Endo M, Ozawa H, Fujikawa R, Tomioka Y, Namba K, Matsubara T, Suzuki J, Watanabe H, Takada K, Hoshino H, Kaiho T, Toyoda T, Kouki Y, Shiono S, Soh J, Ohde Y. Katsumata S, et al. Among authors: shimokawa m. Eur J Cancer. 2024 Apr;201:113951. doi: 10.1016/j.ejca.2024.113951. Epub 2024 Feb 22. Eur J Cancer. 2024. PMID: 38417299
Treatment-related adverse events of combination chemoimmunotherapy versus chemotherapy alone in first-line treatment for non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials.
Takada K, Takamori S, Mizuki F, Miura N, Shikada Y, Shimokawa M. Takada K, et al. Among authors: shimokawa m. J Thorac Dis. 2024 Jan 30;16(1):430-438. doi: 10.21037/jtd-23-1532. Epub 2024 Jan 10. J Thorac Dis. 2024. PMID: 38410572 Free PMC article.
435 results